Literature DB >> 6852112

Reduction of myocardial infarction and dysrhythmic activity by nafazatrom in the conscious rat.

V B Fiedler.   

Abstract

The effects of nafazatrom (30 and 100 mg/kg b.i.d.) on myocardial lesions caused by coronary artery ligation were determined in rats. The treatment lasted ten days preceding and twenty days following the cardiac insult, and its effects were compared with the effects of oral 1% Tylose suspension as drug vehicle. Nafazatrom reduced the number of extrasystoles and the duration of ventricular tachycardia and fibrillation occurring in the early (0-10 min) and late phases (2-4 h) of cardiac arrhythmias observed in the controls. Pretreatment with nafazatrom reduced the size of the ultimate infarct by 36 and 48 percent (P less than 0.05), and by 28 and 39% (P less than 0.05) with post-ligature nafazatrom treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6852112     DOI: 10.1016/0014-2999(83)90016-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

Review 1.  Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation.

Authors:  Hugh Clements-Jewery; David J Hearse; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

2.  The effects of ablations in the central nervous system on arrhythmias induced by coronary occlusion in the rat.

Authors:  M J Curtis; B A Macleod; M J Walker
Journal:  Br J Pharmacol       Date:  1985-11       Impact factor: 8.739

3.  The effects of nafazatrom in an acute occlusion-reperfusion model of canine myocardial injury.

Authors:  V B Fiedler; M Mardin; E Perzborn; R Grützmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

4.  CD271+ Human Mesenchymal Stem Cells Show Antiarrhythmic Effects in a Novel Murine Infarction Model.

Authors:  Haval Sadraddin; Ralf Gaebel; Anna Skorska; Cornelia Aquilina Lux; Sarah Sasse; Beschan Ahmad; Praveen Vasudevan; Gustav Steinhoff; Robert David
Journal:  Cells       Date:  2019-11-20       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.